151 related articles for article (PubMed ID: 37439769)
1. Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures.
Ghosh S; Villacorta-Martin C; Lindstrom-Vautrin J; Kenney D; Golden CS; Edwards CV; Sanchorawala V; Connors LH; Giadone RM; Murphy GJ
Amyloid; 2023 Dec; 30(4):379-393. PubMed ID: 37439769
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
3. Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration.
Ibrahim RB; Yeh SY; Lin KP; Ricardo F; Yu TY; Chan CC; Tsai JW; Liu YT
Cell Mol Life Sci; 2020 Apr; 77(7):1421-1434. PubMed ID: 31728576
[TBL] [Abstract][Full Text] [Related]
4. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.
Giadone RM; Liberti DC; Matte TM; Rosarda JD; Torres-Arancivia C; Ghosh S; Diedrich JK; Pankow S; Skvir N; Jean JC; Yates JR; Wilson AA; Connors LH; Kotton DN; Wiseman RL; Murphy GJ
Stem Cell Reports; 2020 Aug; 15(2):515-528. PubMed ID: 32735824
[TBL] [Abstract][Full Text] [Related]
5. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
7. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
9. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
10. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases.
Park GY; Jamerlan A; Shim KH; An SSA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216785
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and biophysical properties of an unreported T96R mutation causing transthyretin cardiac amyloidosis.
Jiang M; Wang M; Tao Z; Chai Y; Liu Q; Lu Q; Wu Q; Ying X; Huang Y; Nie Y; Tang Y; Zhang X; Liu Y; Pu J
Amyloid; 2023 Jun; 30(2):188-198. PubMed ID: 36350689
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
14. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
15. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis.
Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH
Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264
[TBL] [Abstract][Full Text] [Related]
16. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
18. The proteome response to amyloid protein expression in vivo.
Gomes RA; Franco C; Da Costa G; Planchon S; Renaut J; Ribeiro RM; Pinto F; Silva MS; Coelho AV; Freire AP; Cordeiro C
PLoS One; 2012; 7(11):e50123. PubMed ID: 23185553
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity.
Frangolho A; Correia BE; Vaz DC; Almeida ZL; Brito RMM
Molecules; 2020 Dec; 25(23):. PubMed ID: 33287192
[TBL] [Abstract][Full Text] [Related]
20. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
